Parvus Therapeutics Company Profile
Parvus Therapeutics Inc. is a privately held biopharmaceutical company
engaged in the development and commercialization of Navacim
therapeutics, novel nanoparticle based immune complexes that induce the
in-vivo expansion of disease-specific T- and B-regulatory cells
resulting in the restoration of immune homeostasis. Navacims can be
readily be tailored to target a broad range of autoimmune diseases and
have the potential to radically improve the lives of patients suffering
from these diseases.
News Articles
Roche’s Genentech agrees to buy Jecure Therapeutics
Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CE...
HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics
The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop d...
Indalo Therapeutics Names Robert Jacks President & CEO
Indalo Therapeutics has appointed Robert Jacks to serve as president and CEO. Jacks was most recently president and chief financial officer of Symbiomix Therapeutics, which was acquired by Lupin in 20...
Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics
Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact The...
Dermatology start-up Hoth Therapeutics files for IPO
Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for an initial public offering. The company plans to offer 1.75mm shares at a $...
HiFiBio acquires H-Immune Therapeutics
HiFiBio Therapeutics acquired French biotech H-Immune Therapeutics, a privately held firm developing immuno-oncology therapies. Financial terms were not disclosed.
SMi Group announces the 10th Annual RNA Therapeutics Conference
20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunother...
e-therapeutics, Novo Nordisk enter into research collaboration deal
Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which curre...
Drugs and Medications
Kynamro [kastle therapeutics, llc]
NA
Olopatadine hydrochloride [somerset therapeutics, llc]
OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC
Oxygen [breathe easy therapeutics, inc]
NA
Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]
Diclofenac Sodium
Olopatadine hydrochloride [a-s medication solutions]
OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC
PubMed Articles
The great diversity of dinosaurian tooth shapes and sizes, and in particular, the amazing dental complexity in derived ornithischians has attracted a lot of attention. However, the evolution of dental...
Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...
RNA-targeted therapeutics for lipid disorders.
To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.
Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...
Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.
In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.
Clinical Trials
Impact of Ibis on Patients With Advanced COPD
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Companies
Parvus Therapeutics Inc. is a privately held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune co...
Parvus Therapeutics Inc. is a privately-held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune co...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...
Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...
More Information about "Parvus Therapeutics" on BioPortfolio
We have published hundreds of Parvus Therapeutics news stories on BioPortfolio along with dozens of Parvus Therapeutics Clinical Trials and PubMed Articles about Parvus Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Parvus Therapeutics Companies in our database. You can also find out about relevant Parvus Therapeutics Drugs and Medications on this site too.
